Holen Sie sich die Stockscreener-App
5.7119
0.35%
0.0481
Schlusskurs vom Vortag:
$5.76
Offen:
$5.79
24-Stunden-Volumen:
5,288
Relative Volume:
0.03
Marktkapitalisierung:
$36.09M
Einnahmen:
$4.71M
Nettoeinkommen (Verlust:
$-90.32M
KGV:
-0.6563
EPS:
-8.7032
Netto-Cashflow:
$-85.19M
1W Leistung:
-6.92%
1M Leistung:
+3.40%
6M Leistung:
-17.72%
1J Leistung:
-48.48%
1-Tages-Spanne:
$5.65
$6.02
1-Wochen-Bereich:
$5.62
$6.48
52-Wochen-Spanne:
$3.98
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Firmenname
Aligos Therapeutics Inc
Sektor
Branche
Telefon
(800) 466-6059
Adresse
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.78 | 35.97M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2025-08-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-09 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
Liquidity Mapping Around (ALGS) Price Events - Stock Traders Daily
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - investingnews.com
Why is Aligos Therapeutics stock rallying 7% today? - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why is Aligos Therapeutics stock rallying 7% today? By Investing.com - Investing.com India
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates - Yahoo Finance
Stock Market News - Investing.com South Africa
Aligos Therapeutics (ALGS) Stock Forum and Discussion - Moomoo
Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors - TipRanks
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Why (ALGS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Industry Analysts Just Upgraded Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts By 68% - Moomoo
Aligos Therapeutics (ALGS) Slips 1.55% to $6.67 as Biotech Stock Holds Above Key SupportSector Leader Stocks - vinanet.vn
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Investing News Network
Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China - TradingView
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com South Africa
Aligos Begins Testing a Chronic Hepatitis B Candidate in China - Stock Titan
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics Inc (NASDAQ:ALGS) - intelligentinvestor.com.au
ALGS Q2 2026 Earnings: Narrowed Loss Beats Estimates by 87% as Stock Advances 1.45Healthcare Earnings Report - Vinanet
Cantor Fitzgerald Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Aligos earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Aligos Therapeutics Inc For: 6 August - Investing.com India
Aligos Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News - Quiver Quantitative
Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingView
ALGS: $27.8M licensing revenue drove a smaller Q2 loss; cash runway into Q4 2026, funding needed - TradingView
Aligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock Titan
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView
ALGS: Pipeline advances and licensing deals strengthen financials and outlook for HBV therapies - TradingView
ALIGOS THERAPEUTICS Q2 NET INCOME USD -1.504 MILLION - Moomoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Yahoo Finance
ALGS Q2'26 Earnings: EPS estimate is (1.09) USD - TradingView
Aligos Therapeutics, Inc. expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Rises 0.87% to $4.64, Holds Above SupportKey Reversal Day - dars.gov.et
Earnings Preview: ALGS to Report Financial Results Pre-market on August 06 - moomoo.com
Aligos Therapeutics Inc expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Edges Higher as Biotech Sector Shows Mixed SignalsMACD Signal Stocks - vinanet.vn
Aligos Therapeutics Inc (ALGS) Cash Flow - TradingKey
Aligos Therapeutics Inc (ALGS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALGS|Aligos Therapeutics Inc|Price:7.600|Chg%:+2.010 - TradingKey
ALGS|Aligos Therapeutics Inc|Price:4.075|Chg%:-0.005 - TradingKey
Aligos Therapeutics Inc (ALGS) Income Statement - TradingKey
Aligos Therapeutics Inc (ALGS) Balance Sheet - TradingKey
Finanzdaten der Aligos Therapeutics Inc-Aktie (ALGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):